Abstract:RNA binding proteins have emerged as central players in the mechanisms of many neurodegenerative diseases. In particular, a proteinopathy of fused in sarcoma (FUS) is present in some instances of familial Amyotrophic lateral sclerosis (ALS) and about 10% of sporadic FTLD. Here we establish that focal injection of sonicated human FUS fibrils into brains of mice in which ALS-linked mutant or wild-type human FUS replaces endogenous mouse FUS is sufficient to induce focal cytoplasmic mislocalization and aggregation of mutant and wild-type FUS which with time spreads to distal regions of the brain. Human FUS fibril-induced FUS aggregation in the mouse brain of humanized FUS mice is accelerated by an ALS-causing FUS mutant relative to wild-type human FUS. Injection of sonicated human FUS fibrils does not induce FUS aggregation and subsequent spreading after injection into naive mouse brains containing only mouse FUS, indicating a species barrier to human FUS aggregation and its prion-like spread. Fibril-induced human FUS aggregates recapitulate pathological features of FTLD including increased detergent insolubility of FUS and TAF15 and amyloid-like, cytoplasmic deposits of FUS that accumulate ubiquitin and p62, but not TDP-43. Finally, injection of sonicated FUS fibrils is shown to exacerbate age-dependent cognitive and behavioral deficits from mutant human FUS expression. Thus, focal seeded aggregation of FUS and further propagation through prion-like spread elicits FUS-proteinopathy and FTLD-like disease progression.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore whether the aggregation of Fused in Sarcoma (FUS) protein and its spread in the nervous system can trigger a disease progression similar to Frontotemporal Dementia (FTLD). Specifically, researchers injected pre - formed FUS fibrils into the brains of mice expressing human FUS protein (including wild - type and ALS - related mutant types) to observe whether these fibrils could induce FUS aggregation and whether this aggregation would spread over time in different regions of the brain. In addition, the study also explored whether this aggregation would lead to neurodegenerative lesions and the impact on the cognitive and behavioral functions of mice. ### Research Background - **FUS Protein**: FUS is an RNA - binding protein, usually located in the nucleus. However, in some patients with familial Amyotrophic Lateral Sclerosis (ALS) and about 10% of sporadic Frontotemporal Dementia (FTLD), FUS will be mis - located to the cytoplasm and form aggregates. - **Prion - like Propagation**: Recent studies have shown that proteins in certain neurodegenerative diseases (such as α - synuclein, tau protein, Aβ - peptide, etc.) can spread between cells in a prion - like manner, leading to the accumulation of pathological proteins and the progression of the disease. ### Research Methods - **Animal Model**: Use a humanized FUS mouse model, in which the mouse FUS gene is replaced by the human FUS gene (wild - type or R521H mutant type). - **Experimental Design**: Inject pre - formed FUS fibrils into the brains of 16 - month - old mice and observe the time - dependent and spatial distribution of FUS aggregation. - **Behavioral Tests**: Evaluate the behavioral and cognitive functions of mice through open - field test, rotarod test and novel object recognition test. ### Main Findings - **Induction of FUS Aggregation**: After injecting FUS fibrils, FUS aggregation can be observed at the injection site, and this aggregation gradually spreads to brain regions far from the injection site over time. - **Pathological Features**: The pathological features caused by FUS aggregation are similar to those of FTLD, including cytoplasmic deposition of FUS, accumulation of ubiquitin and p62, etc. - **Behavioral Impact**: Mice injected with FUS fibrils show an exacerbation of age - dependent cognitive and behavioral deficits. ### Conclusions - **Propagation Mechanism of FUS Aggregation**: Injection of FUS fibrils can induce FUS aggregation, and this aggregation spreads in the nervous system in a prion - like manner, ultimately leading to a disease progression similar to FTLD. - **Clinical Significance**: This finding helps to understand the mechanism of FUS in ALS and FTLD and provides new ideas for the development of treatment strategies for these diseases. Through these studies, the authors have revealed the propagation mechanism of FUS aggregation in the nervous system, providing an important scientific basis for further research and treatment of ALS and FTLD.

Frontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS

Frontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS

Nucleation and dissolution mechanism underlying amyotrophic lateral sclerosis/frontotemporal lobar dementia-linked fused in sarcoma condensates

Synaptic accumulation of FUS triggers age-dependent misregulation of inhibitory synapses in ALS-FUS mice

Cytoplasmic aggregation of mutant FUS causes multistep RNA splicing perturbations in the course of motor neuron pathology

Dysfunction in nonsense-mediated decay, protein homeostasis, mitochondrial function, and brain connectivity in ALS-FUS mice with cognitive deficits

Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-κB inhibition

FUS-regulated RNA metabolism and DNA damage repair: Implications for amyotrophic lateral sclerosis and frontotemporal dementia pathogenesis.

Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy

Molecular Determinants and Genetic Modifiers of Aggregation and Toxicity for the ALS Disease Protein FUS/TLS

ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function.

Expression of Human FUS Protein in Drosophila Leads to Progressive Neurodegeneration

Abl kinase-mediated FUS Tyr526 phosphorylation alters nucleocytoplasmic FUS localization in FTLD-FUS

Investigation of a Fused in Sarcoma Splicing Mutation in a Chinese Amyotrophic Lateral Sclerosis Patient.

Mutation of the ALS-/FTD-Associated RNA-Binding Protein FUS Affects Axonal Development

Aberrant Phase Separation of FUS Leads to Lysosome Sequestering and Acidification

FUS-regulated RNA metabolism and DNA damage repair

Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis

Mutations in FUS lead to synaptic dysregulation in ALS-iPSC derived neurons

FUS Interacts with HSP60 to Promote Mitochondrial Damage.

Targeting FUS-ALS aggregation with Proteasome Inhibitors